Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -152,320 | -454,025 | -331,567 | -258,569 | -136,141 |
| Depreciation Amortization | 5,982 | 19,845 | 14,204 | 8,999 | 4,307 |
| Accounts receivable | 33 | -5,432 | -2,362 | -1,669 | -1,993 |
| Accounts payable and accrued liabilities | -16,164 | 32,313 | 1,920 | N/A | N/A |
| Other Working Capital | -11,689 | -63,236 | -83,925 | -87,027 | -77,256 |
| Other Operating Activity | 56,637 | 131,840 | 117,379 | 113,564 | 51,737 |
| Operating Cash Flow | $-117,521 | $-338,695 | $-284,351 | $-224,702 | $-159,346 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 24,702 | -201,180 | -250,094 | -187,185 | -166,010 |
| PPE Investments | -32,184 | -73,093 | -57,045 | -36,485 | -16,414 |
| Sale Of Investment | N/A | 79,843 | 43,197 | N/A | N/A |
| Purchase Sale Intangibles | -30,000 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -29,880 | -942 | -487 | 0 | 0 |
| Investing Cash Flow | $-37,362 | $-195,372 | $-264,429 | $-223,670 | $-182,424 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,755 | 119,044 | 33,177 | 25,503 | 12,761 |
| Other Financing Activity | -143 | -492 | -350 | -226 | -112 |
| Financing Cash Flow | $1,612 | $118,552 | $32,827 | $25,277 | $12,649 |
| Exchange Rate Effect | -108 | -1,194 | -802 | -323 | -771 |
| Beginning Cash Position | 309,585 | 726,294 | 726,294 | 726,294 | 726,294 |
| End Cash Position | 156,206 | 309,585 | 209,539 | 302,876 | 396,402 |
| Net Cash Flow | $-153,379 | $-416,709 | $-516,755 | $-423,418 | $-329,892 |
| Free Cash Flow | |||||
| Operating Cash Flow | -117,521 | -338,695 | -284,351 | -224,702 | -159,346 |
| Capital Expenditure | -32,184 | -73,093 | -57,045 | -36,485 | -16,414 |
| Free Cash Flow | -149,705 | -411,788 | -341,396 | -261,187 | -175,760 |